Home/Vivace Therapeutics/Amy Pfeiffer, MBA

AP

Amy Pfeiffer, MBA

Head of Operations

Vivace Therapeutics

Therapeutic Areas

Vivace Therapeutics Pipeline

Drug	Indication	Phase
VT3989	Refractory pleural and non-pleural mesothelioma; Advanced solid tumors with NF2 mutations	Phase 1/2

Leadership Team at Vivace Therapeutics

Sofie Qiao, Ph.D.

President and Chief Executive Officer

Neelesh Sharma, M.D., Ph.D.

Chief Medical Officer

Tracy Tang, Ph.D.

VP of Biology / Head of Biology

Andrei W. Konradi, Ph.D.

Head of Chemistry

View full Vivace Therapeutics profile